141 related articles for article (PubMed ID: 12781187)
1. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sawa M; Kurokawa K; Inoue Y; Kondo H; Yoshino K
Bioorg Med Chem Lett; 2003 Jun; 13(12):2021-4. PubMed ID: 12781187
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Duan JJ; Lu Z; Xue CB; He X; Seng JL; Roderick JJ; Wasserman ZR; Liu RQ; Covington MB; Magolda RL; Newton RC; Trzaskos JM; Decicco CP
Bioorg Med Chem Lett; 2003 Jun; 13(12):2035-40. PubMed ID: 12781190
[TBL] [Abstract][Full Text] [Related]
3. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.
Levin JI; Chen J; Du M; Hogan M; Kincaid S; Nelson FC; Venkatesan AM; Wehr T; Zask A; DiJoseph J; Killar LM; Skala S; Sung A; Sharr M; Roth C; Jin G; Cowling R; Mohler KM; Black RA; March CJ; Skotnicki JS
Bioorg Med Chem Lett; 2001 Aug; 11(16):2189-92. PubMed ID: 11514167
[TBL] [Abstract][Full Text] [Related]
4. Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity.
Solomon A; Rosenblum G; Gonzales PE; Leonard JD; Mobashery S; Milla ME; Sagi I
J Biol Chem; 2004 Jul; 279(30):31646-54. PubMed ID: 15102849
[TBL] [Abstract][Full Text] [Related]
5. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.
Sawa M; Kiyoi T; Kurokawa K; Kumihara H; Yamamoto M; Miyasaka T; Ito Y; Hirayama R; Inoue T; Kirii Y; Nishiwaki E; Ohmoto H; Maeda Y; Ishibushi E; Inoue Y; Yoshino K; Kondo H
J Med Chem; 2002 Feb; 45(4):919-29. PubMed ID: 11831904
[TBL] [Abstract][Full Text] [Related]
6. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
Bioorg Med Chem Lett; 2001 Nov; 11(22):2907-10. PubMed ID: 11677124
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
9. Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.
Sawa M; Kondo H; Nishimura S
Bioorg Med Chem Lett; 2002 Feb; 12(4):581-4. PubMed ID: 11844676
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.
Letavic MA; Axt MZ; Barberia JT; Carty TJ; Danley DE; Geoghegan KF; Halim NS; Hoth LR; Kamath AV; Laird ER; Lopresti-Morrow LL; McClure KF; Mitchell PG; Natarajan V; Noe MC; Pandit J; Reeves L; Schulte GK; Snow SL; Sweeney FJ; Tan DH; Yu CH
Bioorg Med Chem Lett; 2002 May; 12(10):1387-90. PubMed ID: 11992783
[TBL] [Abstract][Full Text] [Related]
12. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
13. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.
Xue CB; He X; Roderick J; Corbett RL; Duan JJ; Liu RQ; Covington MB; Newton RC; Trzaskos JM; Magolda RL; Wexler RR; Decicco CP
Bioorg Med Chem Lett; 2003 Dec; 13(24):4293-7. PubMed ID: 14643312
[TBL] [Abstract][Full Text] [Related]
14. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
15. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
[TBL] [Abstract][Full Text] [Related]
16. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
Lukacova V; Zhang Y; Kroll DM; Raha S; Comez D; Balaz S
J Med Chem; 2005 Apr; 48(7):2361-70. PubMed ID: 15801829
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.
Letavic MA; Barberia JT; Carty TJ; Hardink JR; Liras J; Lopresti-Morrow LL; Mitchell PG; Noe MC; Reeves LM; Snow SL; Stam EJ; Sweeney FJ; Vaughn ML; Yu CH
Bioorg Med Chem Lett; 2003 Oct; 13(19):3243-6. PubMed ID: 12951101
[TBL] [Abstract][Full Text] [Related]
19. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme.
Wei S; Kashiwagi M; Kota S; Xie Z; Nagase H; Brew K
J Biol Chem; 2005 Sep; 280(38):32877-82. PubMed ID: 16079149
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
